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Adenosine plays a role in pulmonary arterial (PA) resistance due to its vasodilator properties. However, the behavior of adenosine
plasmalevels (APLs) during pulmonary embolism remains unknown.We investigated the eﬀects of gradual pulmonary embolism
on right ventricular (RV) contractility and PA coupling and on APLs in an piglet experimental model of RV failure. PA distal
resistance by pressure-ﬂow relationships and pulmonary vascular impedance were measured. RV contractility was determined by
the end-systolic pressure-volume relationship (Ees), PA eﬀective elastance by the end-diastolic to end-systolic relationship (Ea),
and RV-PA coupling eﬃciency by the Ees/Ea ratio. APLs were measured before and during gradual pulmonary embolization. PA
embolism increased PA resistance and elastance, increased Ea from 1.08 ± 0.15 to 5.62 ± 0.32mmHg/mL, decreased Ees from
1.82 ± 0.10 to 1.20 ± 0.23mmHg/mL, and decreased Ees/Ea from 1.69 ± 0.15 to 0.21 ± 0.07. APLs decreased from 2.7 ± 0.26 to
1.3 ± 0.12μM in the systemic bed and from 4.03 ± 0.63 to 2.51 ± 0.58μM in the pulmonary bed during embolism procedure.
Pulmonary embolism worsens PA hemodynamics and RV-PA coupling. APLs were reduced, both in the systemic and in the
pulmonary bed, leading then to pulmonary vasoconstriction.
1.Introduction
It is generally assumed that acute pulmonary embolism-
induced pulmonary hypertension results from the inter-
action of main factors such as mechanical obstruction of
pulmonary vessels associated with PA constriction [1]. In
this setting, RV outﬂow impedance is suddenly increased
[2], RV ejection fraction is impaired, and the RV is enlarged
[3]. Thus, both systolic and diastolic functions are impaired,
which may cause or precipitate circulatory failure in criti-
cally ill patients. Experimental models of acute pulmonary
embolism with autologous clots have also been reported
[2–6]. Acute pulmonary embolism-induced pulmonary
hypertension was shown to persistently deteriorate RV
contractility by increasing RV afterload, thereby provid-
ing a rationale for inotropic support [4]. Other factors
such as PA constriction attributable to neurogenic reﬂex
and hypoxia and release of vasoconstrictors by activated
platelets, leukocytes, and endothelial and lung cells could
be involved [1]. Among these, adenosine (ADO), a purine
nucleoside released by vascular endothelium and myocytes,
may be implicated in the control of healthy and pathologic
pulmonary circulation [7, 8]. ADO has strong vasodila-
tory properties via the activation of G-coupled membrane
receptors, namely, A1, A2A, A2B or A3 depending on their
aﬃnity for ADO or agonists and primary sequence [9]. Thus
extracellular ADO concentration is crucial for the control of
systemic and pulmonary blood pressure. High concentration2 ISRN Cardiology
of ADO can activate, low aﬃnity adenosine receptors, faci-
litating vasodilation. However, to our knowledge, there is
no data on the behavior of endogenous ADO plasma levels
(APLs) during acute pulmonary hypertension following pul-
monary embolization.
Therefore, our purpose was to evaluate RV performance,
pulmonary hemodynamics, RV-vascular coupling, and their
correlation to APLs in that model of RV failure. To better
identify and quantify the PA and RV components of the
experimental model and ofthepharmacologicinterventions,
we will assess the pulmonary circulation by PA pressure-ﬂow
curvesand PAimpedance and theventricular function byRV
end-systolic elastance and RV-PA coupling eﬃciency [10].
2.Materialsand Methods
All experiments were approved by the Animal Ethics Com-
mittee of the University School of Medicine and were done
in accordance with the “Guiding Principles in the Care and
Use of Animals” of the American Physiological Society.
2.1. Preparation. The study included 10 pi´ etrain pigs (mean
weight 40kg) premedicated with midazolam 0.2mg·kg−1
and ketamine 20mg·kg−1 i.m., anesthetized with midazo-
lam i.v. 0.2mg·kg−1 and 0.2mg·kg−1·h−1,a n dp a r a l y z e d
for thoracotomy with vecuronium bromide i.v. 1mg·kg−1
and 2mg·kg−1·h−1.S u f e n t a n i l0 . 5μg·kg−1 i.v.w a sg i v e na t
time of induction and again at beginning of surgery, and
10–20μg boluses were added to prevent increases in heart
rate or blood pressure. Other details of the preparation have
been published previously in [10, 11]. Brieﬂy, the pigs were
initially ventilated with an inspired oxygen fraction of 0.4,
tidal volume of 12mL/kg, a respiratory rate to achieve a
PaCO2 of 35–40mmHg, and a plateau pressure below 30cm
of water. A positive end-expiratory pressure of 5cm of water
wasusedtoavoidatelectasisformation.APAcatheter(131H-
7F, Baxter-Edwards, Irvine, Calif) was inserted, and normal
saline was infused to maintain the occluded PA pressure
between 5 and 10mmHg. A balloon catheter (Percor,
Datascope,Paramus, NJ)wasadvanced intotheinferior vena
cava to decrease cardiac output by reducing venous return.
A median sternotomy was performed, and a 16 to 24mm
ultrasonic ﬂow probe (T206, Transonic, Ithaca, NY) was
positioned around the main pulmonary artery. Manometer-
tipped catheters (SPC 350, Millar, Houston, Tex) were
introduced into the right ventricle and proximal pulmonary
artery. Then, chest was closed, but no attempt was made to
restore a negative intrathoracic pressure.
2.2. Data Analysis. Instantaneous pressures and ﬂow were
sampled at 200Hz. PA resistance was assessed by pressure-
ﬂow relationships obtained byrapid ﬂow reduction. PA pres-
sure values were interpolated at ﬂows of 2 and 4L/min/m2
from individual regressions and were averaged to obtain
composite pressure-ﬂow plots. A single beat method was
applied to compute RV end-systolic elastance (Ees) as the
slope of the end-systolic pressure-volume line, PA eﬀective
elastance (Ea) as the absolute slope of the end-systolic to
end-diastolic line, and ventriculoarterial coupling eﬃciency
as the Ees/Ea ratio. This method has been validated dur-
ing variations of preload, afterload, and inotropism and
has provenreliable in conditionsof pulmonary hypertension
and RV failure [11–13].
Pulmonary vascular impedance spectrum (PVZ)was cal-
culated from the Fourier series expressions for pressure
and ﬂow signals as previously reported in [10]. Five end-
expiratory heartbeats are analyzed for each data-collection
interval. The PVZ modulus was computed as the ratio
betweenpressure andﬂowmoduli,anditsphaseiscomputed
as the diﬀerence between ﬂow and pressure phases. The
impedance at 0Hz (Zo) was taken as the total resistance
(Ppa/Q), and characteristic impedance (Zc) was calculated
as the average of impedance moduli between 2 and 15Hz.
From the PVZ spectra were also derived the ﬁrst harmonic
modulus (Z1) and the ﬁrst harmonic phase angle (Ph1).
2.3. Protocol. Each data set included ﬂow and pressure
values collected at steady state for calculation of impedance
and RV-PA coupling and collected during a ﬂow reduction
maneuver for construction of pressure-ﬂow relations. A ﬁrst
data set was obtained after 30 minutes of postoperative
stabilization, during a transient period of apnea following
the end of expiratory phase. The same procedure was
repeated 30min after each injection of autologous blood
clots. For this purpose, a 250mL blood sample, collected
before sternotomy, was allowed to clot in a beaker and
was cut into 3 to 5mm pieces for injection. A large bore
polyethylene cannula (ID 12 French) was inserted into the
left external jugular vein, and blood clot pieces were injected
by an irrigation syringe over 30min. Embolization was
carriedoutprogressivelyuntilreached30–35mmHginaﬁrst
step,Ppa40–45mmHginasecondstep,and50–55mmHgin
a third step. The Ppa stabilized after 30min at a levelthat was
in general 3–5mmHg below the value achieved at the end
of embolization. A complete set of measurements was also
taken at each step. Thereafter, for each level of Ppa, arterial
blood gases and APLs levels were also recorded.
At the end of the study, each animal was killed by intra-
venous injection of potassium chloride, under deep intra-
venous anesthesia.
2.4. Samples Collection. ADO was measured at baseline and
for each step of pulmonary embolism (just 1 minute before
hemodynamic measurements). Blood samples were taken
from both carotid and pulmonary arteries. ADO sample
collection and treatment have been previously described in
[7, 8]. Brieﬂy, the lumens of the arterial and pulmonary
catheters were washed out and ﬁlled with a solution of 1mL
of papaverine and 1mL of dipyridamole, injected through
the lateral entry of a 3-way stopcock just prior to blood
sampling.
2.5. ADO Assay. Samples were immediately centrifuged,
deproteinated(perchloricacid,70%),and lyophilized,before
beinganalyzedbychromatographyaspreviouslydescribedin
[14, 15].ISRN Cardiology 3
0
10
20
30
40
50
P
A
p
r
e
s
s
u
r
e
(
m
m
H
g
)
∗
24
Cardiac output (L/min/m2)
Baseline
Embolism phase 1
Embolism phase 2
Embolism phase 3
Figure 1: Pulmonary arterial (PA) pressure versus cardiac output
plots at baseline and after pulmonary embolism (highest level)
(mean ± s.e.m, n = 10). Pressure-ﬂow plots shifted upwards with
embolism. ∗P<. 05 versus baseline.
2.6.Statistical Analysis. Hemodynamic, APLs,andmetabolic
variables were analyzed by a repeated-measures analysis of
variance followed by Fisher’s protected t-tests. P<. 05 was
considered statistically signiﬁcant. Spearman correlation was
performed between mean PA pressure, mean PA elastance,
and APLs. Data were expressed as mean (s.e.m). Statistical
analysis was performed using SPSS software, version 11.5 for
Windows.
3.Results
3.1.Baseline. Hemodynamicandbloodgasdataarereported
in Tables 1 and 2. APLs were signiﬁcantly higher in the
distal pulmonary artery than in the carotid artery. Ppa/Q
plots were linear with correlation coeﬃcients from 0.96 to
1. Representative Ppa/Q plots are shown in Figure 1.
3.2. Eﬀects of Pulmonary Embolism. PA embolism increased
heart rate, PA, and right atrial pressures and decreased pro-
gressively cardiac output. Systemic arterial pressure was sig-
niﬁcantly reduced only at the third step (Table 1). Pressure-
ﬂow plots were shifted upwards (Figure 1). Impedance
spectra were also shifted upwards, with increased Zo and
Zc, and more negative low-frequency phases (Figure 2). Ea
increased from about 1.08 to 5.62mmHg/mL, Ees initially
increased inthe ﬁrst twosteps butdecreased from about1.82
to 1.20mmHg/mL, and Ees/Ea markedly decreased from
about 1.69 to 0.21 at the third step of embolism (Figure 3).
Lung embolization was associated with marked decreases
in arterial pH, O2 tension, and APLs (Table 3)a n dw i t h
increases in arterial CO2 tension (Table 2). In every instance,
APLs were higher in the distal pulmonary arteries than
in the systemic circulation. Correlation between mean PA
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Figure 2: Pulmonary vascular impedance spectra at baseline and
after gradual pulmonary embolism (mean ± s.e.m, n = 10). The
impedance spectrum shifted upwards during embolism.
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Figure 3: Right ventriculopulmonary arterial (PA) coupling eﬃ-
ciency assessed as the ratio of ventricular end-systolic elastance
(Ees) to eﬀective arterial elastance (Ea) at baseline and after gradual
pulmonary embolism (mean ± s.e.m, n = 10). Gradual embolism
markedly and persistently decreased Ees/Ea. ∗P<. 05 versus
baseline.4 ISRN Cardiology
Table 1: Hemodynamics before and after gradual pulmonary artery embolism.
Baseline Embolism 1 Embolism 2 Embolism 3
Heart rate, bpm 90 ±8 122 ± 8a 135 ±9a 148 ± 8ab
CO, L/min/m2 4.1 ±0.13 .3 ±0.4a 2.7 ±0.3a 1.7 ±0.3abc
Psa, mmHg 110 ±10 119 ±11 106 ±88 8 ±8abc
Ppa, mmHg 18 ±23 1 ±3a 39 ±3ab 47 ±4abc
Pra, mmHg 7 ±17 ± 19 ±2ab 10 ± 1ab
Ppao, mmHg 7 ±17 ±11 1 ±1ab 12 ± 1ab
Zo, dyn·s·cm−5·m2 530 ± 45 1704 ±244a 2268 ±190ab 3498 ±208abc
Zc, dyn·s·cm−5·m2 92 ±13 265 ±30a 297 ±59a 416 ±43abc
Fm i n ,H z 3 .40 ±0.25 4.90 ±0.50a 4.88 ±0.71 4.92 ± 0.53a
Ph1, rad −0.32 ±0.03 −0.57 ± 0.08a −0.55 ±0.09a −0.65 ±0.10a
Ees, mmHg/mL 1.82 ±0.10 2.70 ±0.06a 2.28 ±0.42a 1.20 ±0.23abc
Ea, mmHg/mL 1.08 ±0.15 3.15 ±0.13a 4.22 ±0.40ab 5.62 ±0.32abc
Ees/Ea 1.69 ±0.15 0.86 ±0.28a 0.54 ±0.25a 0.21 ±0.07abc
SV, mL 41 ±32 7 ±2a 18 ±2ab 12 ±3abc
Valuesaremeans ±SE(n = 10).CO:cardiacoutput;Psa:systemicarterialpressure;Ppa:pulmonaryarterialpressure;Pra:rightatrialpressure;Ppao:occluded
Ppa; Zo: 0-Hz impedance; Zc: characteristic impedance; Ees: end-systolic elastance; Ea: arterial elastance. aP<. 05 versus baseline; bP<. 05 versus embolism
1; cP<. 05 versus embolism 2.
Table 2: Respiratory parameters before and during pulmonary artery embolism.
Baseline Embolism 1 Embolism 2 Embolism 3
pH 7.40 ± 0.01 7.34 ± 0.02a 7.30 ± 0.01ab 7.25 ± 0.02abc
PaO2, mmHg 164 ± 20 120 ± 20a 88 ±12a 51 ± 5abc
PaCO2, mmHg 36 ± 13 9 ± 5a 48 ±5ab 62 ± 6abc
Values are means ± s.e.m (n = 10).
aP<. 05 versus baseline; bP<. 05 versus embolism 1; cP<. 05 versus embolism 2.
Table 3: Plasmaticvalues of adenosine before and during pulmonary artery embolism.
Baseline Embolism 1 Embolism 2 Embolism 3
Carotid artery, μmoL/L 2.73 ±0.26 1.79 ±0.26a 1.99 ± 0.28a 1.30 ± 0.12abc
Pulmonary artery, μmoL/L 4.03 ±0.63 2.44 ±0.42a 2.98 ± 0.5a 2.51 ±0.58a
Values are means ± s.e.m (n = 10).
aP<. 05 versus baseline; bP<. 05 versus embolism 1; cP<. 05 versus embolism 2.
pressures, mean Ea and pulmonary artery APLs at all levels
was negative (r =− 0.64; P<. 01 and r =− 0.79, P<. 01,
resp.).
4.Discussion
The present results (I) demonstrate that an acute pressure
overload following pulmonary embolismby autologousclots
induces a RV failure, (II) show that the RV-PA uncoupling
is due both to an increase in PA resistance and elastance
and to a depression of RV contractility, and (III) suggest
that adenosine release by pulmonary vascular endothelium
is reduced following pulmonary embolism.
4.1. Pulmonary Arterial Changes. In addition to PA pressure
and resistance, we used ﬂow-pressure curves to better detect
resistance changes due to distal small muscular arteries [16]
and pulmonary vascular impedance to assess elastic changes
duetolargeproximalarteries[17].Zcistheratioofinertance
versus compliance of the proximal pulmonary arteries and
varies directly with the elastic modulus of the vessel and
indirectly with its cross-sectional area [17]. In our study,
Zc remained abnormal and indicated an increased elas-
tance (increased stiﬀness decreased compliance) of proximal
vessels, contributing to increased wave reﬂections and to
an increased RV afterload. Similar Zc changes have also
been reported previously after PA constriction [11]. This
persistence of changes could result from a sympathetic
stimulation due to the transient low cardiac output and
hypotension [10] or from an activation of stretch receptors
due to the PA vasoconstriction [18].
It was reported that transient PA hypertension following
autologous blood clot embolic pulmonary hypertension was
associated with an increase of pulmonary vascular tone
and PVZ spectra in mammals [2]. Pulmonary embolism
induced by autologous blood clots in pigs has been reported
to increase PVR, Zo, Zc, and phase angle negativity [4].ISRN Cardiology 5
Our results concur. But pulmonary embolism induced by
150–200μm glass beads or in dogs was associated with a
decrease of Zc [19]. A decrease in Zc could be explained
by dilatation of the PA tree. These discrepancies could be
due to the diﬀerent types of acute pulmonary embolism
(autologous clots versus glass beads).
4.2. Right Ventricular Changes. RV contractility was clearly
increased after the ﬁrst and second steps of embolization,
as evidenced by a signiﬁcant Ees augmentation. This feature
is in agreement with Ghuysen et al.’s study [6] suggesting
that increment in Ea following pulmonary embolism could
be initially coupled with preload recruitment to maintain
RV performance. But RV contractility remained altered
after the third step of PA embolism (Ees changed from
1.82 to 1.20mmHg/mL), while afterload remained increased
suggesting that the combination of both factors results
in a marked deterioration of RV-PA coupling eﬃciency.
In contrast with Ghuysen’s study, our data showed in
response to several gradual afterload increases (3 steps of
embolisms) that RV-PA coupling was not maintained at
maximal eﬃciencylevelbecauseofasharp increase ofEaand
mean Ppa (47mmHg in our study versus 30mmHg in their
study).AnotherexperimentalstudyshowedthatoptimalRV-
PA coupling could be maintained in dogs after distal PA
embolism by 0.5-mm glass beads [20]. These results are
consistent with the concept that most of the load imposed
on the right ventricle is contained in the proximal PA tree,
so that an increase in distal resistance (Zo) will depress RV
performance and output less than an increase in proximal
elastance (Zc and Ea) [20]. The second discrepancy with
Wauthy et al.’s experimental study could be due to the choice
ofanimal model.Dogsarealsoknowntohavegoodcollateral
ventilation, experience less local hypoxia than pigs and
then require less hypoxic pulmonary vasoconstriction and
show less extensive muscularity than pigs [21]. The diﬀerent
types of protocols could also explain why RV coupling was
preserved in a previous study when dynamic RV afterload
was increased about twofold [6, 20] and why it deteriorated
here when resistance was sixfold increased. The RV changes
could perhaps result from RV myocardial stunning due to
hypotension and RV ischemia [22] or to other yet undeﬁned
humoral,chemical, ormechanical factors. Finally, changes in
coupling values obtained in our study also were comparable
tothosereported in patients with leftventricular failure[23].
4.3. APLs and Pulmonary Embolism. In every instance, APLs
were higher in the distal pulmonary arteries than in the
systemic circulation. The short half-life of ADO argues
against the hypothesis that ADO withdrawn from the distal
pulmonary artery was released in the whole circulation [24].
It supports the assumption that ADO is released essentially
locallyorupstream,nearthesamplingsite,bythepulmonary
vascular endothelium [8].
Gradual pulmonary embolization was associated with
signiﬁcant reductions of O2 tension and APLs. But there
is no evidence that PaO2 has any eﬀect on ADO uptake,
because ADO could cross into red cells via an equilibrative
transporter [24]. Therefore, pulmonary tissue ischemia due
to either low ﬂow or hypoxia should result in ADO release.
This has been experimentally shown on normal canine lung
tissue [25]. Although exogenous ADO was shown to inhibit
hypoxic pulmonary vasoconstriction in isolated rat lungs
[26], it is not clear how endogenous ADO acts in the
regulation of pulmonary blood ﬂow and hypoxic pulmonary
vasoconstriction. Moreover, the correlation between mean
PA pressures, mean Ea and APLs suggests that ADO could
play a role in the regulation of pulmonary vascular tone.
Elevated PA pressures may promote and accelerate pul-
monary vascular wall damage [27]. Since ADO is released by
endothelial cells [28], one can hypothesize that pulmonary
vascular endothelium injured by embolism becomes unable
to release enough ADO to stimulate low-aﬃnity spare
receptors [29] which could promote pulmonary vasodila-
tion. Finally, it is well established that systemic vascular
obstruction is followed by a strong increase in APLs, due to
the ischemic process [30]. Here we found that pulmonary
bed obstruction was followed by a decrease in APLs. Because
itiswell establishedthatADOreducespulmonaryresistances
[8], the low concentration in APLs could contribute to an
increase of PA hypertension in our model.
5.StudyLimitations
Wedonotexplorewhetherthepulmonary adenosineadmin-
istration could prevent part of the abnormalities; however,
this should be done in further studies.
6.Conclusion
Acute pulmonary embolism-induced pulmonary hyperten-
sion deteriorates right ventricular-pulmonary arterial cou-
pling both by increasing PA resistance and elastance and by
decreasing RV contractility, thereby conﬁrming a rationale
for both inotropic and pulmonary vasodilatory support. In
this context, low ADO concentrations may be the result of
theinjuredpulmonaryvascularendothelium,leadingthento
anincreaseofpulmonaryvasoconstriction.Finally,thisstudy
suggests that ADO infusion could be an adjuvant treatment
for pulmonary embolism.
Abbreviations
ADO: Adenosine
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Ea: Aﬀective pulmonary arterial elastance
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PA: Pulmonary arterial
Ppa: Mean pulmonary arterial pressure
Psa: Mean systemic arterial pressure
Q: Pulmonary artery ﬂow
RV: Right ventricular
RV-PA: Right ventricular-vascular coupling (right
ventricular-pulmonary arterial coupling).6 ISRN Cardiology
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